Coverage Decisions and the Court: A Public Health Perspective on Glucosamine Reimbursement in Thailand

Abstract —Thailand achieves universal health coverage through the introduction of three benefit schemes: the Civil Servant Medical Benefit Scheme (CSMBS), Social Security Scheme, and Universal Coverage Scheme. The primary benefit package of these schemes includes all medicines referenced in the National List of Essential Medicines. However, the CSMBS pays for nonessential drugs (NEDs) for particular conditions.  The CSMBS's cost escalation prompted the Ministry of Finance to tightly control drug expenditure. In 2010, glucosamine—an NED—was prohibited from CSMBS reimbursement. Subsequently, a dispute was lodged at the Administrative Court by two CSMBS beneficiaries. The court ruled that glucosamine reimbursement should be reinstated in the CSMBS scheme based on two grounds: the Royal College of Orthopedic Surgeons of Thailand's clinical practice guidelines and an argument with reference to Article 78(8) of the 2007 Constitution mandating the state to provide appropriate benefits to government and state officials.  Our comments are based on two factors: (1) the integrity of evidence that the Court applied and (2) the ruling with reference to Constitution Article 78(8) as it conflicts with Article 51, which aims to ensure equal rights to health services by all citizens. Because court cases concerning health care coverage in Thailand may expand in the future, we call upon the public to discuss the following issue: whether the court should rule on the inclusion of particular interventions or whether it should focus on the integrity of the coverage decision-making process. Similar lessons can be drawn from the experiences of countries in Latin America and Europe. In any case, all concerned parties including the court should be equipped with a good understanding of the complexity of the country's health systems in either option.

[1]  Lei Wu,et al.  Clinical practice guidelines for hypertension in China: a systematic review of the methodological quality , 2015, BMJ Open.

[2]  A. Rosoff,et al.  Evidence-Based Medicine and the Law: The Courts Confront Clinical Practice Guidelines , 2001, Journal of health politics, policy and law.

[3]  J. Grimshaw,et al.  Potential benefits, limitations, and harms of clinical guidelines , 1999, BMJ.

[4]  Pablo Alonso-Coello,et al.  The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies , 2010, Quality and Safety in Health Care.

[5]  C. M. Vargas-Peláez,et al.  Right to health, essential medicines, and lawsuits for access to medicines--a scoping study. , 2014, Social science & medicine.

[6]  G. Tognoni,et al.  Appraisal of Five Clinical Guidelines for the Management of Hypertension in Andean Countries and Europe , 2014 .

[7]  K. Syrett Health technology appraisal and the courts: accountability for reasonableness and the judicial model of procedural justice , 2010, Health Economics, Policy and Law.

[8]  Y. Teerawattananon,et al.  Efficiency or equity: value judgments in coverage decisions in Thailand. , 2012, Journal of health organization and management.

[9]  Y. Teerawattananon,et al.  The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. , 2014, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[10]  Michelle E. Kho,et al.  AGREE II: advancing guideline development, reporting and evaluation in health care , 2010, Canadian Medical Association Journal.

[11]  J. Carroll The diagnosis-related group (DRG) system. , 2010, Quality management in health care.

[12]  John P A Ioannidis,et al.  Ensuring the integrity of clinical practice guidelines: a tool for protecting patients , 2013, BMJ : British Medical Journal.

[13]  A. Mills,et al.  Health sector regulation in Thailand: recent progress and the future agenda. , 2003, Health policy.

[14]  Christa Rautenbach,et al.  The Constitutional Court of South Africa , 2017 .

[15]  R. Barata,et al.  Legal suits: pharmaceutical industry strategies to introduce new drugs in the Brazilian public healthcare system. , 2010, Revista de saude publica.

[16]  N. Daniels,et al.  Role of the Courts in the Progressive Realization of the Right to Health: Between the Threat and the Promise of Judicialization in Mexico , 2015, Health systems and reform.